Yicheng Kangtai Biotechnology

Beijing Yicheng Kangtai Biotechnology is a clinical-stage biopharmaceutical company focused on the development of innovative immune cell therapies for the treatment of cancer. The company leverages its proprietary technology platforms to engineer T cells, including Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor-engineered T-cell (TCR-T) therapies. Its pipeline targets a range of indications, including hematological malignancies and challenging solid tumors such as liver cancer and lung cancer. Yicheng Kangtai is dedicated to advancing precision medicine through high-affinity TCR screening and optimized CAR constructs. The company is headquartered in Beijing and actively conducts clinical trials in collaboration with leading medical institutions in China.